← boardnext 2026-09
TTIPF
Thiogenesis Therapeutics, Inc.distress 5/10 · elevated risk$0.420%today-28% from 52w high
Lead: Leigh Syndrome
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
—
Price & events
-28.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
-6.7%
3M
-28.0%
6M
+26150.0%
1Y
—
2Y
—
5Y
+1.2%
All
Overview
- Volume
- 0
- 52 Week Range
- $0.00 – $0.58
- Float Shares
- 42.93M
- % Held by Insiders
- 12.73%
- % Held by Institutions
- 0.00%
- Beta
- 0.57
Pipeline stages · 1 programs
TTI-0102: cysteamine-pantetheine disulfide, D-Mannitol
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | TTI-0102: cysteamine-pantetheine disulfide, D-Mannitol | Leigh Syndrome | — | not yet recruiting |
Catalyst news & presentations · 1
- 2026-08-25Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Leigh Syndrome
- none identified
Recent news
- 2026-07-14If You Invested $1,000 in Thiogenesis (TTIPF) - Stock Titan
- 2026-07-13FDA rare pediatric disease status for Leigh syndrome drug TTI-0102 - Stock Titan
- 2026-07-13Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome - TMX Newsfile
- 2026-06-17Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors - TMX Newsfile
- 2026-06-01Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares - TMX Newsfile
- 2026-04-01Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.